Report cover image

Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 197 Pages
SKU # APRC20356155

Description

Summary

According to APO Research, The global Vascular Endothelial Growth Factor (VEGF) Antibodies market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Vascular Endothelial Growth Factor (VEGF) Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Vascular Endothelial Growth Factor (VEGF) Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Vascular Endothelial Growth Factor (VEGF) Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Vascular Endothelial Growth Factor (VEGF) Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Vascular Endothelial Growth Factor (VEGF) Antibodies include Sanofi, Novartis, Merck, Roche, Eli Lilly, Pfizer, GlaxoSmithKline, Bayer and AstraZeneca, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Vascular Endothelial Growth Factor (VEGF) Antibodies, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Vascular Endothelial Growth Factor (VEGF) Antibodies, also provides the sales of main regions and countries. Of the upcoming market potential for Vascular Endothelial Growth Factor (VEGF) Antibodies, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Vascular Endothelial Growth Factor (VEGF) Antibodies sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Vascular Endothelial Growth Factor (VEGF) Antibodies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Vascular Endothelial Growth Factor (VEGF) Antibodies sales, projected growth trends, production technology, application and end-user industry.

Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Company

Sanofi
Novartis
Merck
Roche
Eli Lilly
Pfizer
GlaxoSmithKline
Bayer
AstraZeneca
Regeneron
Bristol-Myer Squibb
Boehringer Ingelheim
Abcam Plc
Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Type

Aflibercept
Bevacizumab
Ranibizumab
Others
Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Application

Specialty Clinics
Hospitals
Ambulatory Surgical Centers
Cancer Research Institutes
Others
Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vascular Endothelial Growth Factor (VEGF) Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vascular Endothelial Growth Factor (VEGF) Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vascular Endothelial Growth Factor (VEGF) Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vascular Endothelial Growth Factor (VEGF) Antibodies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Vascular Endothelial Growth Factor (VEGF) Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Vascular Endothelial Growth Factor (VEGF) Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Vascular Endothelial Growth Factor (VEGF) Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size, 2020 VS 2024 VS 2031
1.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size Estimates and Forecasts (2020-2031)
1.4 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Estimates and Forecasts (2020-2031)
1.5 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Dynamics
2.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Trends
2.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Drivers
2.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Opportunities and Challenges
2.4 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Restraints
3 Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Manufacturers
3.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Manufacturers (2020-2025)
3.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Manufacturers (2020-2025)
3.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Average Sales Price by Manufacturers (2020-2025)
3.4 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Manufacturers, Product Type & Application
3.7 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market CR5 and HHI
3.8.2 Global Top 5 and 10 Vascular Endothelial Growth Factor (VEGF) Antibodies Players Market Share by Revenue in 2024
3.8.3 2024 Vascular Endothelial Growth Factor (VEGF) Antibodies Tier 1, Tier 2, and Tier 3
4 Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Type
4.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Type Introduction
4.1.1 Aflibercept
4.1.2 Bevacizumab
4.1.3 Ranibizumab
4.1.4 Others
4.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type
4.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Type (2020-2031)
4.2.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Type (2020-2031)
4.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type
4.3.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Type (2020-2031)
4.3.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Type (2020-2031)
5 Vascular Endothelial Growth Factor (VEGF) Antibodies Market by Application
5.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Application Introduction
5.1.1 Specialty Clinics
5.1.2 Hospitals
5.1.3 Ambulatory Surgical Centers
5.1.4 Cancer Research Institutes
5.1.5 Others
5.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application
5.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Application (2020-2031)
5.2.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Application (2020-2031)
5.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application
5.3.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Application (2020-2031)
5.3.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Application (2020-2031)
6 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region
6.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region (2020-2031)
6.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region (2020-2025)
6.2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region
7.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region
7.1.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region (2020-2025)
7.1.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region (2026-2031)
7.1.4 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2020-2031)
7.2.2 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2020-2031)
7.3.2 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2020-2031)
7.4.2 Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Sanofi
8.1.1 Sanofi Comapny Information
8.1.2 Sanofi Business Overview
8.1.3 Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.1.5 Sanofi Recent Developments
8.2 Novartis
8.2.1 Novartis Comapny Information
8.2.2 Novartis Business Overview
8.2.3 Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.2.5 Novartis Recent Developments
8.3 Merck
8.3.1 Merck Comapny Information
8.3.2 Merck Business Overview
8.3.3 Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.3.5 Merck Recent Developments
8.4 Roche
8.4.1 Roche Comapny Information
8.4.2 Roche Business Overview
8.4.3 Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.4.5 Roche Recent Developments
8.5 Eli Lilly
8.5.1 Eli Lilly Comapny Information
8.5.2 Eli Lilly Business Overview
8.5.3 Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.5.5 Eli Lilly Recent Developments
8.6 Pfizer
8.6.1 Pfizer Comapny Information
8.6.2 Pfizer Business Overview
8.6.3 Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.6.5 Pfizer Recent Developments
8.7 GlaxoSmithKline
8.7.1 GlaxoSmithKline Comapny Information
8.7.2 GlaxoSmithKline Business Overview
8.7.3 GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.7.5 GlaxoSmithKline Recent Developments
8.8 Bayer
8.8.1 Bayer Comapny Information
8.8.2 Bayer Business Overview
8.8.3 Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.8.5 Bayer Recent Developments
8.9 AstraZeneca
8.9.1 AstraZeneca Comapny Information
8.9.2 AstraZeneca Business Overview
8.9.3 AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.9.5 AstraZeneca Recent Developments
8.10 Regeneron
8.10.1 Regeneron Comapny Information
8.10.2 Regeneron Business Overview
8.10.3 Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.10.5 Regeneron Recent Developments
8.11 Bristol-Myer Squibb
8.11.1 Bristol-Myer Squibb Comapny Information
8.11.2 Bristol-Myer Squibb Business Overview
8.11.3 Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.11.5 Bristol-Myer Squibb Recent Developments
8.12 Boehringer Ingelheim
8.12.1 Boehringer Ingelheim Comapny Information
8.12.2 Boehringer Ingelheim Business Overview
8.12.3 Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.12.5 Boehringer Ingelheim Recent Developments
8.13 Abcam Plc
8.13.1 Abcam Plc Comapny Information
8.13.2 Abcam Plc Business Overview
8.13.3 Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Product Portfolio
8.13.5 Abcam Plc Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Value Chain Analysis
9.1.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Vascular Endothelial Growth Factor (VEGF) Antibodies Production Mode & Process
9.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Distributors
9.2.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.